Condition: Hematologic Neoplasms · Sponsor: National Cancer Institute, Slovakia
Numerous in vitro and animal studies as well as growing number of clinical studies support the important role of microbiome in carcinogenesis and cancer treatment. Detection of changes in patients´ microbiome following hematopoietic cell transplantation/CAR-T cell therapy and correlations with adverse transplant outcomes, mainly infectious complications, acute and chronic GvHD, disease recurrence etc. could serve as predictive markers of immune recovery and treatment response.
This description comes directly from the study's public registry record.
Barbora Kašperová, MD · +421-2-59378272 · barbora.kasperova@nou.sk
Sona Ciernikova, PhD · +421-2-59378273 · sona.ciernikova@savba.sk
Always discuss trial participation with your own doctor first.
| National Cancer Institute | Bratislava, Slovakia, Slovakia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04691284